{"id":47138,"date":"2022-08-10T14:01:57","date_gmt":"2022-08-10T12:01:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/"},"modified":"2022-08-10T14:01:57","modified_gmt":"2022-08-10T12:01:57","slug":"ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/","title":{"rendered":"Ocular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference"},"content":{"rendered":"
\n

BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL<\/a> #OCUTX<\/a>–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022:\n<\/p>\n

<\/a><\/p>\n

\nPre-Recorded Corporate Presentation
\n
<\/b>Date: Wednesday, August 17, 2022
\n
Time: 7:00 AM ET\n<\/p>\n

\nPanel Discussion – Unique Delivery Technology Platforms for Better Compliance and Efficacy
\n
<\/b>Date: Wednesday, August 17, 2022
\n
Time: 11:00 AM ET\n<\/p>\n

\nThe management team will host investor meetings on Wednesday, August 17th<\/sup> at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their H.C. Wainwright representative.\n<\/p>\n

\nA webcast of the pre-recorded corporate presentation and the panel discussion can be accessed by visiting the Investors section of the Company\u2019s website at investors.ocutx.com and will remain available for replay for 90 days.\n<\/p>\n

\nAbout Ocular Therapeutix, Inc.
\n
<\/b>Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix\u2019s first commercial drug product, DEXTENZA\u00ae, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix\u2019s earlier stage development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other retinal diseases; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, both of which have completed Phase 2 clinical trials. Ocular Therapeutix’s first product, ReSure\u00ae Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors<\/b>
Ocular Therapeutix
\n
Donald Notman
\n
Chief Financial Officer
\n
dnotman@ocutx.com<\/a>\n<\/p>\n

\nor\n<\/p>\n

\nICR Westwicke
\n
Chris Brinzey, 339-970-2843
\n
Managing Director
\n
chris.brinzey@westwicke.com<\/a>\n<\/p>\n

\nMedia<\/b>
Ocular Therapeutix
\n
Scott Corning
\n
Senior Vice President, Commercial
\n
scorning@ocutx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022: Pre-Recorded Corporate Presentation Date: Wednesday, August 17, 2022 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47138","6":"format-standard","7":"category-industry"},"yoast_head":"\nOcular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022: Pre-Recorded Corporate Presentation Date: Wednesday, August 17, 2022 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-10T12:01:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220810005126\/en\/807582\/21\/OCUTX_Logo_RGB_1200x700_FINAL.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ocular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference\",\"datePublished\":\"2022-08-10T12:01:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/\"},\"wordCount\":372,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220810005126\\\/en\\\/807582\\\/21\\\/OCUTX_Logo_RGB_1200x700_FINAL.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220810005126\\\/en\\\/807582\\\/21\\\/OCUTX_Logo_RGB_1200x700_FINAL.jpg\",\"datePublished\":\"2022-08-10T12:01:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220810005126\\\/en\\\/807582\\\/21\\\/OCUTX_Logo_RGB_1200x700_FINAL.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220810005126\\\/en\\\/807582\\\/21\\\/OCUTX_Logo_RGB_1200x700_FINAL.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference - Pharma Trend","og_description":"BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022: Pre-Recorded Corporate Presentation Date: Wednesday, August 17, 2022 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-10T12:01:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220810005126\/en\/807582\/21\/OCUTX_Logo_RGB_1200x700_FINAL.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ocular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference","datePublished":"2022-08-10T12:01:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/"},"wordCount":372,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220810005126\/en\/807582\/21\/OCUTX_Logo_RGB_1200x700_FINAL.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/","url":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/","name":"Ocular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220810005126\/en\/807582\/21\/OCUTX_Logo_RGB_1200x700_FINAL.jpg","datePublished":"2022-08-10T12:01:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220810005126\/en\/807582\/21\/OCUTX_Logo_RGB_1200x700_FINAL.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220810005126\/en\/807582\/21\/OCUTX_Logo_RGB_1200x700_FINAL.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ocular-therapeutix-to-present-at-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47138"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47138\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}